In this article
Obesity and Cancer Risk: An Umbrella Review
Obesity not only runs counter to the aesthetics of people, but also causes many chronic diseases. Some studies have shown that body mass index (BMI) is related to the risk of cancer in certain parts (such as the digestive system), but there is no unified conclusion on the relationship with cancer in other parts. An umbrella review published in Annals of Oncology at the end of 2017, comprehensively analyzing the relationship between 26 BMI and cancer riskta analysis, and strive to bring the most authoritative conclusions to readers.
Study Methodology and Scope
The study only included evaluation of the quantitative response between BMI and the risk of cancer analysis, a total of 26 articles. Use umbrella review (ie multiple meta analysis to review), re-analyzed the relationship between BMI and 20 types of cancer.
Strength of Association by Cancer Type
The results of the study showed that five types of cancer (leukemia, multiple myeloma, pancreatic cancer, endometrial cancer, rectal cancer, and renal cell carcinoma) had the highest correlation strength with BMI; three types of cancer (malignant melanoma, non-Hodgkin) Lymphoma and esophageal adenocarcinoma) and BMI reach a moderate level of strength; for brain and central nervous system tumors, breast cancer, colon cancer, gallbladder cancer, lung cancer, liver cancer, ovarian cancer and thyroid cancer, there is a low-grade BMI Degree of association; there is no association between the occurrence of bladder cancer, gastric cancer and prostate cancer and BMI.
The relationship between increased BMI and the occurrence of cancer varies greatly between different cancers. According to analysis, the occurrence of leukemia, multiple myeloma, pancreatic cancer, endometrial cancer, rectal cancer and renal cell carcinoma is strongly associated with the increase in BMI.
Body mass index and 20-specific cancers: re-analyses of dose-response meta-analyses of observational studies. Ann Oncol. 2017 Dec 28. doi: 10.1093 / annonc / mdx819.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Susan Hau
Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy. Hau's expertise lies in cancer cell biolo…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.